{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-003690","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-07-29T20:05:46+00:00","discovered_at":"2026-07-29T20:07:00.561217+00:00","generated_at":"2026-07-29T20:07:36.611839+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion initiates Phase 2/3 trial of SIL204 in pancreatic cancer at Tel Aviv Sourasky Medical Center","bullets":["First clinical site activated at Tel Aviv Sourasky Medical Center; patient screening to begin in coming weeks.","Phase 2/3 trial of SIL204 (siRNA) for locally advanced pancreatic cancer; follows regulatory approvals from Israeli MoH and German BfArM.","Trial includes safety run-in (~18 patients) then randomized cohort (~166 patients); dual-route administration (intratumoral + systemic).","Additional Israeli and German sites expected to join in coming months; first patient dosing anticipated as next milestone.","SIL204 targets broad range of KRAS mutations; KRAS mutations present in ~90% of pancreatic cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-003690","json":"https://secwatch.observer/filing/0001178913-26-003690.json","markdown":"https://secwatch.observer/filing/0001178913-26-003690.md","text":"https://secwatch.observer/filing/0001178913-26-003690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/0001178913-26-003690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/zk2635763.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:07:36.611839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}